DE69828874D1 - Zusammensetzungen und verfahren zur eliminierung unerwünschter zellen - Google Patents

Zusammensetzungen und verfahren zur eliminierung unerwünschter zellen

Info

Publication number
DE69828874D1
DE69828874D1 DE69828874T DE69828874T DE69828874D1 DE 69828874 D1 DE69828874 D1 DE 69828874D1 DE 69828874 T DE69828874 T DE 69828874T DE 69828874 T DE69828874 T DE 69828874T DE 69828874 D1 DE69828874 D1 DE 69828874D1
Authority
DE
Germany
Prior art keywords
compositions
syncytium
unwanted cells
inducing polypeptide
eliminating unwanted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69828874T
Other languages
English (en)
Other versions
DE69828874T2 (de
Inventor
Stephen James Russell
Frances Joanne Morling
Adele Kay Fielding
Francois-Loic Cosset
Roberto Cattaneo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mayo Foundation for Medical Education and Research
Original Assignee
Mayo Foundation for Medical Education and Research
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9705007.4A external-priority patent/GB9705007D0/en
Application filed by Mayo Foundation for Medical Education and Research filed Critical Mayo Foundation for Medical Education and Research
Application granted granted Critical
Publication of DE69828874D1 publication Critical patent/DE69828874D1/de
Publication of DE69828874T2 publication Critical patent/DE69828874T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16622—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
    • C12N2710/16722—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/13043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/13045—Special targeting system for viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper
    • C12N2760/18422—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18611—Respirovirus, e.g. Bovine, human parainfluenza 1,3
    • C12N2760/18622—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18711—Rubulavirus, e.g. mumps virus, parainfluenza 2,4
    • C12N2760/18722—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18811—Sendai virus
    • C12N2760/18822—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/80—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates
    • C12N2810/85—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian
    • C12N2810/851—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian from growth factors; from growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DE69828874T 1997-03-11 1998-03-10 Zusammensetzungen und verfahren zur eliminierung unerwünschter zellen Expired - Lifetime DE69828874T2 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB9705007 1997-03-11
GBGB9705007.4A GB9705007D0 (en) 1997-03-11 1997-03-11 Improvements in or relating to therapeutic genes
US4516497P 1997-04-30 1997-04-30
US45164P 1997-04-30
PCT/GB1998/000710 WO1998040492A1 (en) 1997-03-11 1998-03-10 Compositions and methods for elimination of unwanted cells

Publications (2)

Publication Number Publication Date
DE69828874D1 true DE69828874D1 (de) 2005-03-10
DE69828874T2 DE69828874T2 (de) 2005-07-07

Family

ID=26311163

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69828874T Expired - Lifetime DE69828874T2 (de) 1997-03-11 1998-03-10 Zusammensetzungen und verfahren zur eliminierung unerwünschter zellen

Country Status (8)

Country Link
US (7) US6750206B2 (de)
EP (1) EP0966534B1 (de)
JP (1) JP4422804B2 (de)
AT (1) ATE288488T1 (de)
AU (1) AU744882B2 (de)
CA (1) CA2283536C (de)
DE (1) DE69828874T2 (de)
WO (1) WO1998040492A1 (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998040492A1 (en) * 1997-03-11 1998-09-17 Cambridge Genetics Limited Compositions and methods for elimination of unwanted cells
FR2786773B1 (fr) * 1998-12-03 2002-03-08 Univ Paris Curie Proteines d'enveloppe, methodes et utilisations
WO2000071578A2 (en) * 1999-05-20 2000-11-30 Cnrs Centre National De La Recherche Scientifique New polypeptides and their use for the rescue of fusion defective virus or retrovirus glycoproteins
GB9925966D0 (en) 1999-11-02 1999-12-29 Petrik Juraj Threapeutic vaccines against variable viruses and other targets
AU2001251138A1 (en) * 2000-03-31 2001-10-15 Mayo Foundation For Medical Education And Research Compositions and methods for tissue specific gene regulation therapy
US20020187543A1 (en) * 2001-04-05 2002-12-12 Curiel David T. Enhanced dispersion of adenoviral vectors by fusogenic membrane glycoproteins
US20040265805A1 (en) * 2002-05-02 2004-12-30 Monsanto Technology, L.L.C. Method for cloning large DNA
GB0317511D0 (en) 2003-07-25 2003-08-27 Biovex Ltd Viral vectors
WO2008144067A1 (en) * 2007-05-21 2008-11-27 Board Of Regents, University Of Texas System Methods and compositions for treatment of cancer using oncolytic rsv activity
US11414491B2 (en) 2016-05-18 2022-08-16 Mayo Foundation For Medical Education And Research Targeting PD-L1 on tumor cells

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2140380T5 (es) * 1990-03-21 2005-03-16 Geneart Gmbh Secuencias de adn que codifican polipeptidos gag retroviricos modificados y vacunas que las contienen o agregados de las mismas.
US5847096A (en) * 1991-08-30 1998-12-08 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services DNA constructs encoding CD4 fusion proteins
US5420011A (en) * 1993-04-12 1995-05-30 The United States Of America As Represented By The Department Of Health And Human Services Cell bioassay for neurotoxins
GB9308963D0 (en) 1993-04-30 1993-06-16 Smithkline Beecham Biolog Novel compounds
US6015686A (en) * 1993-09-15 2000-01-18 Chiron Viagene, Inc. Eukaryotic layered vector initiation systems
US5753499A (en) * 1994-12-23 1998-05-19 New York University Viral vector complexes having adapters of predefined valence
EP0839044B1 (de) 1995-03-31 2005-05-18 Universite Libre De Bruxelles DENDRITENZELLEN/TUMORZELLEN Hybirde ZUR INDUKTION EINER ANTI-TUMOR ANTWORT
US5674734A (en) 1995-05-18 1997-10-07 President And Fellows Of Harvard College Cell death protein
GB9514368D0 (en) 1995-07-13 1995-09-13 Medical Res Council Improvements in or relating to binding assays
US5869036A (en) * 1995-12-08 1999-02-09 St. Louis University Live attenuated vaccines based on CP45 HPIV-3 strain and method to ensure attenuation in such vaccine
DE19605279A1 (de) * 1996-02-13 1997-08-14 Hoechst Ag Zielzellspezifische Vektoren für die Einschleusung von Genen in Zellen, Arzneimittel enthaltend derartige Vektoren und deren Verwendung
WO1998040492A1 (en) 1997-03-11 1998-09-17 Cambridge Genetics Limited Compositions and methods for elimination of unwanted cells
US5882893A (en) * 1997-12-04 1999-03-16 Millennium Pharmaceuticals, Inc. Nucleic acids encoding muscarinic receptors and uses therefor

Also Published As

Publication number Publication date
JP2001522232A (ja) 2001-11-13
US20080171026A1 (en) 2008-07-17
US7317004B2 (en) 2008-01-08
US20080227740A1 (en) 2008-09-18
AU744882B2 (en) 2002-03-07
JP4422804B2 (ja) 2010-02-24
AU6408498A (en) 1998-09-29
US7846429B2 (en) 2010-12-07
EP0966534A1 (de) 1999-12-29
US20030095947A1 (en) 2003-05-22
DE69828874T2 (de) 2005-07-07
US20080171027A1 (en) 2008-07-17
WO1998040492A1 (en) 1998-09-17
CA2283536C (en) 2009-09-01
US20060051335A1 (en) 2006-03-09
EP0966534B1 (de) 2005-02-02
ATE288488T1 (de) 2005-02-15
US6750206B2 (en) 2004-06-15
US7314868B2 (en) 2008-01-01
US20080226610A1 (en) 2008-09-18
CA2283536A1 (en) 1998-09-17
US20040253214A1 (en) 2004-12-16

Similar Documents

Publication Publication Date Title
NO885659D0 (no) Mycobakterielle rekombinanter og peptider.
ES2009238A6 (es) Metodo para producir proteinas de mycobacterium tuberculosis y peptidos antigenicos de las mismas.
AR056723A2 (es) Polipeptido purificado metodo para producirlo , metodo para identificarlo y/ o aislarlo composicion farmaceutica que lo comprende, secuencia de acidos nucleicos aislada que codifica dicho polipeptido, vector que contiene a dicha secuencia celula huesped transfectada por dicho vector, sonda nucleotid
BR9813608B1 (pt) célula hospedeira de bacillus transgênica, e, processo para produzir um polipeptìdeo tendo atividade aminopeptidase.
DK1005540T3 (da) IKK-beta-proteiner, nukleinsyrer og fremgangsmåder
ATE64151T1 (de) Rekombinante immunoglobulin-praeparate, verfahren zu ihrer herstellung, dna-sequenzen, expressionsvektoren und rekombinante wirkzellen hierfuer.
MY120693A (en) Human bikunin
ATE466948T1 (de) Dns-basiertes transposon-system für die einführung von nucleinsäure in die dns einer zelle
WO1999020766A3 (en) NOVEL MODIFIED NUCLEIC ACID SEQUENCES AND METHODS FOR INCREASING mRNA LEVELS AND PROTEIN EXPRESSION IN CELL SYSTEMS
CA2249233A1 (en) Mch4 and mch5, apoptotic protease, nucleic acids encoding and methods of use
EP0804609A4 (de) NEUARTIGE AUF p53 ANSPRECHENDE GENE
ATE323770T1 (de) Polypeptide mit lysophospholipaseaktivität und nukleinesäuren die sie kodieren
BR0009393A (pt) Polipeptìdeo, sequência de ácido nucleico isolada, construção de ácido nucleico, vetor de expressão recombinante, célula hospedeira recombinante, método para a produção do polipeptìdeo, uso de um polipeptìdeo, e, composição detergente
DE69828874D1 (de) Zusammensetzungen und verfahren zur eliminierung unerwünschter zellen
WO1996015144A3 (en) Chromosome 21 gene marker, compositions and methods using same
DE69535696D1 (de) Tripeptidyl-aminopeptidase
PL1675956T3 (pl) Minimalna sekwencja DNA działająca jako insulator chromatyny i jej zastosowanie do wyrażania białek
ES2152313T3 (es) Gen grb-3-3, sus variantes y sus utilizaciones.
WO1999010504A3 (en) Caspase-14, an apoptotic protease, nucleic acids encoding and methods of use
ATE377649T1 (de) Verfahren und zelle zur expression von rekombinanten proteinprodukten
ATE316138T1 (de) Rekombinante expression von s-layer-proteinen
DE69333304D1 (de) Erhöhte produktion von sekretierten proteinen durch rekombinante eukaryotische zellen
WO2000052164A3 (en) Potassium channel molecules and uses therefor
WO1998051788A3 (en) Method and construct for inhibition of cell migration
WO2001032872A3 (en) Twik potassium channel molecules and uses therefor

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8328 Change in the person/name/address of the agent

Representative=s name: MEISSNER, BOLTE & PARTNER GBR, 80538 MUENCHEN